EDAP TMS (FOCL) Panoramica del titolo
EDAP TMS S.A., che opera come FocalTherics, è un'azienda di tecnologia medica che sviluppa, produce, commercializza e vende dispositivi medici terapeutici non invasivi a ultrasuoni e a energia in Asia, Francia, Stati Uniti e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 1/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 2/6 |
| Dividendi | 0/6 |
FOCL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$10.74
FV
52.1% sottovalutato sconto intrinseco19
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Concorrenti di EDAP TMS S.A.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$5.15 |
| Massimo di 52 settimane | US$5.24 |
| Minimo di 52 settimane | US$1.21 |
| Beta | -0.00048 |
| Variazione di 1 mese | 19.10% |
| Variazione a 3 mesi | 45.75% |
| Variazione di 1 anno | 208.08% |
| Variazione a 3 anni | -44.91% |
| Variazione a 5 anni | -23.09% |
| Variazione dall'IPO | -39.47% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Jun 23
FOCL: Execution And Margin Risks Will Limit Upside Versus Current Pricing
EDAP TMS’s analyst fair value estimate has been reset from $2.50 to $3.00 as analysts factor in updated assumptions on growth, margins and valuation following recent sector research, including coverage of peers in high intensity focused ultrasound technology for prostate cancer treatment. Analyst Commentary Recent Street research on EDAP TMS highlights a mix of optimism around the company’s high intensity focused ultrasound platform and caution around how that potential is reflected in the valuation.
Aggiornamento della narrazione • Jun 04
FOCL: Reaffirmed Outlook And Fair Value Will Support Future Re Rating
Analysts have reduced their price target on EDAP TMS by $4 to reflect updated assumptions on the discount rate, revenue growth, profit margins and future P/E, while maintaining a $10.00 fair value estimate. What's in the News EDAP TMS plans to change its Nasdaq Global Market ticker symbol from EDAP to FOCL, effective June 1, 2026.Aggiornamento della narrazione • May 21
EDAP: Reaffirmed 2026 Outlook Will Support Discount Rate Recalibration
Analysts have lowered their price target on EDAP TMS by $4, citing updated assumptions around the discount rate, revenue growth, profit margins and future P/E as key drivers of the change. Analyst Commentary Bullish analysts highlight that the revised price target, while reduced by US$4, still reflects confidence in EDAP TMS's ability to execute on its business plan and support a valuation that they view as attractive relative to updated assumptions.Recent updates
Aggiornamento della narrazione • Jun 23
FOCL: Execution And Margin Risks Will Limit Upside Versus Current Pricing
EDAP TMS’s analyst fair value estimate has been reset from $2.50 to $3.00 as analysts factor in updated assumptions on growth, margins and valuation following recent sector research, including coverage of peers in high intensity focused ultrasound technology for prostate cancer treatment. Analyst Commentary Recent Street research on EDAP TMS highlights a mix of optimism around the company’s high intensity focused ultrasound platform and caution around how that potential is reflected in the valuation.Aggiornamento della narrazione • Jun 04
FOCL: Reaffirmed Outlook And Fair Value Will Support Future Re Rating
Analysts have reduced their price target on EDAP TMS by $4 to reflect updated assumptions on the discount rate, revenue growth, profit margins and future P/E, while maintaining a $10.00 fair value estimate. What's in the News EDAP TMS plans to change its Nasdaq Global Market ticker symbol from EDAP to FOCL, effective June 1, 2026.Aggiornamento della narrazione • May 21
EDAP: Reaffirmed 2026 Outlook Will Support Discount Rate Recalibration
Analysts have lowered their price target on EDAP TMS by $4, citing updated assumptions around the discount rate, revenue growth, profit margins and future P/E as key drivers of the change. Analyst Commentary Bullish analysts highlight that the revised price target, while reduced by US$4, still reflects confidence in EDAP TMS's ability to execute on its business plan and support a valuation that they view as attractive relative to updated assumptions.Aggiornamento della narrazione • Apr 27
EDAP: Reaffirmed 2026 Revenue Guidance Will Support Refined Upside Thesis
Analysts have trimmed their price target on EDAP TMS by $4, citing updated assumptions around discount rates, revenue growth, and future P/E that refine their view of the company’s risk and earnings profile. Analyst Commentary Bullish analysts acknowledge the $4 trim to the price target as a recalibration to updated discount rate, revenue, and future P/E assumptions, rather than a change in their broader view of EDAP TMS.Aggiornamento della narrazione • Apr 12
EDAP: Revised Outlook Will Rely On 2026 Revenue Guidance Execution
Analysts have lowered their price target on EDAP TMS to $10.00 from $14.00, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts lowering the price target to US$10.00 from US$14.00 reflects updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations rather than a single headline event.
Aggiornamento della narrazione • Mar 29
EDAP: Longer Term Revenue Outlook Will Support Future Upside
Analysts have adjusted their price target on EDAP TMS to $6.83. The change reflects updated assumptions for discount rate, revenue growth, profit margin, and future P/E that are now more closely aligned with their current modeling for the business.Aggiornamento della narrazione • Mar 14
EDAP: 2026 Segment Guidance Will Limit Upside Versus Current Pricing
Analysts have adjusted their price target on EDAP TMS to reflect updated assumptions for revenue growth, profit margins, discount rate and future P/E. This has led to a revised valuation framework that investors should watch closely against the current share price in dollar terms.Aggiornamento della narrazione • Feb 28
EDAP: 2026 Segment Guidance Will Constrain Future Share Price Upside
Analysts have lifted their EDAP TMS price target to reflect updated assumptions for a $2.50 fair value, a slightly higher discount rate, a shift from a 1.0% revenue decline to 20.8% growth expectations, a modestly stronger 13.40% profit margin outlook, and a lower forward P/E of about 11.6x. What's in the News EDAP TMS issued revenue guidance for 2026 for its HIFU business, with a range of $50.0 million to $54.0 million, or €43.0 million to €46.0 million.Aggiornamento della narrazione • Feb 14
EDAP: Flat Revenue Outlook And Higher P/E Assumptions Will Limit Upside
Analysts have raised their $ fair value estimate for EDAP TMS from $1.50 to $2.50, citing updated assumptions that include a lower discount rate, a revenue growth outlook that is closer to flat, slightly higher profit margins, and a higher future P/E multiple. What's in the News Issued 2026 revenue guidance for the HIFU business in a range of $50.0 million to $54.0 million, or €43.0 million to €46.0 million (company guidance).Articolo di analisi • Feb 03
EDAP TMS S.A. (NASDAQ:EDAP) Shares Fly 32% But Investors Aren't Buying For Growth
EDAP TMS S.A. ( NASDAQ:EDAP ) shares have continued their recent momentum with a 32% gain in the last month alone...Aggiornamento della narrazione • Jan 31
EDAP: HIFU Guidance And FDA Clearance Will Support Future Upside
Analysts have adjusted their price target on EDAP TMS to US$25.18 from US$26.39, citing updated assumptions for the discount rate, profit margin and future P/E, which leave their fair value view broadly unchanged. What's in the News EDAP TMS issued 2026 revenue guidance, with HIFU business revenue expected in a range of US$50.0 million to US$54.0 million and non core Distribution and ESWL revenue in a range of US$22.0 million to US$26.0 million, also provided in euro terms as €43.0 million to €46.0 million and €19.0 million to €22.0 million respectively (company guidance).Aggiornamento della narrazione • Jan 17
EDAP: Future Guidance And FDA Clearance Will Support Bullish Upside
Analysts now see higher upside for EDAP TMS, lifting their fair value estimate from about US$5.77 to roughly US$6.83 as they factor in slightly different assumptions around discount rate, revenue growth, profit margins and future P/E levels. What's in the News EDAP TMS issued 2026 revenue guidance, with HIFU business revenue expected in a range of US$50.0 million to US$54.0 million and non core Distribution and ESWL revenue in a range of US$22.0 million to US$26.0 million (Key Developments).Articolo di analisi • Dec 20
EDAP TMS S.A.'s (NASDAQ:EDAP) Price Is Right But Growth Is Lacking After Shares Rocket 32%
EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders would be excited to see that the share price has had a great month, posting...Articolo di analisi • Dec 13
EDAP TMS (NASDAQ:EDAP) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Aggiornamento della narrazione • Aug 29
CE Mark And Global Expansion Will Elevate HIFU Adoption
Despite a modest decline in consensus revenue growth forecasts, EDAP TMS’s sharply higher projected P/E multiple suggests increased investor optimism regarding future earnings quality or profitability, driving the analyst price target up from $5.75 to $14.00. What's in the News EDAP TMS raised its 2025 core HIFU business revenue growth guidance to 26%-34% year over year, up from the previous 16%-25% range.Articolo di analisi • Aug 19
There Is A Reason EDAP TMS S.A.'s (NASDAQ:EDAP) Price Is Undemanding
EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a strong buy right now...Articolo di analisi • Jul 03
Is EDAP TMS (NASDAQ:EDAP) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • May 18
Improved Revenues Required Before EDAP TMS S.A. (NASDAQ:EDAP) Stock's 28% Jump Looks Justified
Those holding EDAP TMS S.A. ( NASDAQ:EDAP ) shares would be relieved that the share price has rebounded 28% in the last...
Nuova narrazione • Apr 08
CE Mark And Global Expansion Will Elevate HIFU Adoption
New approvals and strategic collaborations enhance EDAP TMS's market opportunities, potentially driving future revenue growth and improving margins.Articolo di analisi • Apr 03
EDAP TMS S.A. (NASDAQ:EDAP) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny
EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders that were waiting for something to happen have been dealt a blow with a 27...Articolo di analisi • Mar 15
Is EDAP TMS (NASDAQ:EDAP) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Articolo di analisi • Dec 25
Potential Upside For EDAP TMS S.A. (NASDAQ:EDAP) Not Without Risk
With a price-to-sales (or "P/S") ratio of 1.2x EDAP TMS S.A. ( NASDAQ:EDAP ) may be sending very bullish signals at the...Articolo di analisi • Oct 24
Is EDAP TMS (NASDAQ:EDAP) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Articolo di analisi • Sep 07
Slammed 35% EDAP TMS S.A. (NASDAQ:EDAP) Screens Well Here But There Might Be A Catch
EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders that were waiting for something to happen have been dealt a blow with a 35...Articolo di analisi • Jul 24
Fewer Investors Than Expected Jumping On EDAP TMS S.A. (NASDAQ:EDAP)
EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 2.6x might make it look like a buy right now...Articolo di analisi • Mar 22
There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump
Despite an already strong run, EDAP TMS S.A. ( NASDAQ:EDAP ) shares have been powering on, with a gain of 28% in the...Articolo di analisi • Mar 03
Does EDAP TMS (NASDAQ:EDAP) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Jan 19
It's A Story Of Risk Vs Reward With EDAP TMS S.A. (NASDAQ:EDAP)
With a median price-to-sales (or "P/S") ratio of close to 3.2x in the Medical Equipment industry in the United States...Articolo di analisi • Aug 11
Investors Still Waiting For A Pull Back In EDAP TMS S.A. (NASDAQ:EDAP)
EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 4.7x might make it look like a sell right now...Articolo di analisi • Dec 19
Is There An Opportunity With EDAP TMS S.A.'s (NASDAQ:EDAP) 20% Undervaluation?
Does the December share price for EDAP TMS S.A. ( NASDAQ:EDAP ) reflect what it's really worth? Today, we will estimate...Articolo di analisi • Nov 23
EDAP TMS' (NASDAQ:EDAP) Solid Profits Have Weak Fundamentals
Despite posting some strong earnings, the market for EDAP TMS S.A.'s ( NASDAQ:EDAP ) stock hasn't moved much. We did...Rendimenti per gli azionisti
| FOCL | US Medical Equipment | US Mercato | |
|---|---|---|---|
| 7D | 3.3% | 4.6% | 0.3% |
| 1Y | 208.1% | -21.2% | 19.9% |
Ritorno vs Industria: FOCL ha superato il US Medical Equipment che ha restituito -21.2 % nell'ultimo anno.
Rendimento vs Mercato: FOCL ha superato il mercato US che ha restituito 19.9 % nell'ultimo anno.
Volatilità dei prezzi
| FOCL volatility | |
|---|---|
| FOCL Average Weekly Movement | 7.4% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: FOCL non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 7% ) di FOCL è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1979 | 289 | Ryan Rhodes | investor.focalone.com |
EDAP TMS S.A., che opera come FocalTherics, è una società di tecnologia medica che sviluppa, produce, commercializza e vende dispositivi medici non invasivi a ultrasuoni terapeutici e a energia in Asia, Francia, Stati Uniti e a livello internazionale. L'azienda sviluppa, produce, commercializza e distribuisce sistemi HIFU robotici non invasivi per l'urologia e per altre indicazioni. Offre anche Focal One, un sistema robotico HIFU per il trattamento di pazienti con diagnosi di cancro alla prostata, oltre a materiali monouso, servizi di leasing e di trattamento e servizi di manutenzione.
EDAP TMS S.A. Riepilogo dei fondamenti
| FOCL statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$191.53m |
| Utili (TTM) | -US$30.88m |
| Ricavi(TTM) | US$74.07m |
2.6x
Rapporto P/S-6.2x
Rapporto P/EFOCL è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| FOCL Conto economico (TTM) | |
|---|---|
| Ricavi | US$74.07m |
| Costo del fatturato | US$41.92m |
| Profitto lordo | US$32.15m |
| Altre spese | US$63.04m |
| Utili | -US$30.88m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -0.82 |
| Margine lordo | 43.41% |
| Margine di profitto netto | -41.70% |
| Rapporto debito/patrimonio netto | 240.6% |
Come si è comportato FOCL nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/30 16:47 |
| Prezzo dell'azione a fine giornata | 2026/06/29 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
EDAP TMS S.A. è coperta da 8 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| null null | CG Capital |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |